![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2018
Rule, S.; Jurczak, W.; Jerkeman, M.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; Hess, G.; Bence-Bruckler, I.; Cho, S-G; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.; Vermeulen, J. und Dreyling, M.
(2018):
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
In: Leukemia, Bd. 32, Nr. 8: S. 1799-1803
2017
Davies, A.; Trask, P.; Demeter, J.; Florschütz, A.; Hänel, M.; Hong, X.; Kinoshita, T.; Pettengell, R.; Quach, H.; Robinson, S.; Sadullah, S.; Sancho, J.-M.; Udvardy, M.; Witzens-Harig, M.; Rufibach, K.; Zeuner, H. und Unterhalt, M.
(2017):
Health-Related Quality Of Life Results From The Phase III Gallium Study Of Obinutuzumab-Based And Rituximab-Based Therapy In Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.
In: Haematologica, Bd. 102: S. 190-191
2016
Witzens-Harig, M.; Keller, U.; Viardot, A.; Buske, C.; Hönig, E.; Crombe, A.; Brandt, J.; Meissner, J.; Ho, A.; La Rosee, P.; Marks, R.; Dreyling, M. und Hess, G.
(2016):
Safety and clinical activity of temsirolimus in combination with Rituximab and DHAP in patients with relapsed or refractory diffuse large B-cell lymphoma - preliminary results of the storm trial.
In: Haematologica, Bd. 101: S. 390